Intranasal Nanoemulsion: A Promising Approach for the Management of Parkinson’s Disease

Parkinson's Disease (PD) is a neurodegenerative syndrome defined by the deterioration of dopamine neurons, showing a loss of motor activity. The treatment of PD is still challenging despite the development of numerous management techniques. Blood-brain Barrier (BBB) provides limited access to drug transport, being a major limiting factor in the treatment of Central Nervous System (CNS) disorders. Further, the major challenges in neurodegenerative diseases are low bioavailability and side effects. Intranasal drug delivery has become increasingly accessible for the treatment of several CNS disorders, including PD. The nasal cavity has direct access to the brain and drugs may be delivered at the site of action by bypassing the blood-brain barrier. Therapeutic molecules could be directly delivered to the brain through the olfactory region in the nasal cavity; further, the first-pass effects of drugs could also be eliminated. Several novel and promising developments in non-invasive approaches have been revealed for brain targeting by the nasal route. Among them, Nanoemulsions (NEs)-based drug delivery has been most widely explored, which can assist in several significant issues, such as limited BBB permeability, limited solubility, poor bioavailability, limited onset of action, and less enzymatic degradation. Several research reports have indicated intranasal NEs to have potential brain-targeting abilities, which may be widely explored for the treatment of PD. Therefore, the present review article has focused on the current scenario of intranasal NEs for the management of PD, with recent outcomes outlined through various research studies.